Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: A meta-analysis

Acta Haematologica

Volumn 129, Issue 2, 2013, Pages 90-95

  Zhong, Da Ni ^a   Wu, Ji Zhou ^a   Li, Guo Jian ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Bisphosphonate related osteonecrosis of the jaws; CYP2C8 rs1934951 polymorphism; Meta analysis; Pharmacogenetics

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTOCHROME P450 2C8; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID; CYP2C8 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ARTICLE; DISEASE PREDISPOSITION; EMBASE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; JAW OSTEONECROSIS; MEDLINE; META ANALYSIS; MULTIPLE CANCER; MULTIPLE MYELOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; RISK FACTOR;

ARYL HYDROCARBON HYDROXYLASES; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; DIPHOSPHONATES; HUMANS; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

MLCS; MLOWN;

EID: 84869237892     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000342120     Document Type: Article

References (27)

1. Aft R: Bisphosphonates in breast cancer: clinical activity and implications of preclinical data. Clin Adv Hematol Oncol 2011; 9: 194-205.
2. Gnant M, Hadji P: Prevention of bone metastases and management of bone health in early breast cancer. Breast Cancer Res 2010; 12: 216.
3. Pozzi S, Raje N: The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist 2011; 16: 651-662.
4. Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
5. Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W: Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008; 54: 1066-1072.
6. Stumpe MR, Chandra RK, Yunus F, Samant S: Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws. Head Neck 2009; 31: 202-206.
7. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws -2009 update. J Oral Maxillofac Surg 2009; 67: 2-12.
8. O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, Martin D, Liberty D, Lo JC: Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg 2009; 67: 1363-1372.
9. Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, Bauss F, Ehrenfeld M, Schieker M: Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 2010; 68: 2837-2845.
10. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala PA: Review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548-1558.
11. Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, Santamaria C, Rosinol L, de la Rubia J, Hernandez MT, Garcia-Navarro I, Lahuerta JJ, Gonzalez M, San Miguel JF: Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008; 112: 2709-2712.
12. Such E, Cervera J, Terpos E, Bagan JV, Avaria A, Gomez I, Margaix M, Ibanez M, Luna I, Cordon L, Roig M, Sanz MA, Dimopoulos MA, de la Rubia J: CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica 2011; 96: 1557-1559.
13. Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW, Zhou SF: Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab 2009; 10: 1009-1047.
14. Soh TI, Yong WP, Innocenti F: Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clin Chem Lab Med 2011; 49: 1621-1632.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
16. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
17. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
18. English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD: A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag 2010; 6: 579-583.
19. Balla B, Vaszilko M, Kosa J, Podani J, Takacs I, Tobias B, Nagy Z, Lazary A, Lakatos P: New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw. Oral Dis 2012; 18: 580-585.
20. Katz J, Gong Y, Salmasinia D, Hou W, Burkley B, Ferreira P, Casanova O, Langaee TY, Moreb JS: Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg 2011; 40: 605-611.
21. Chowbay B, Li H, David M, Cheung YB, Lee EJ: Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005; 60: 159-171.
22. Kiyohara C, Yoshimasu K: Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 2007; 4: 59-71.
23. Jung TI, Hoffmann F, Glaeske G, Felsenberg D: Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy. J Cancer Res Clin Oncol 2010; 136: 363-370.
24. Daly AK: Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010; 11: 241-246.
25. Li SC, Tang P, Lin WC: Intronic microRNA: discovery and biological implications. DNA Cell Biol 2007; 26: 195-207.
26. Monteys AM, Spengler RM, Wan J, Tecedor L, Lennox KA, Xing Y, Davidson BL: Structure and activity of putative intronic miRNA promoters. RNA 2010; 16: 495-505.
27. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A: Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91: 968-971.